OJRad  Vol.5 No.3 , September 2015
Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid
Bone scan index (BSI) has been used to quantify the spread of bone metastasis and be a prognostic indicator in prostate cancer with bone metastases. However, the utility of BSI in breast cancer patients with bone metastasis has not been yet established. We retrospectively reviewed 57 female breast cancer patients with osteoblastic/lytic combined type bone metastases and treated with zoledronic acid after bone metastasis was identified. Serial bone scintigrams were taken at the time of bone metastasis detection and during the 6- and 12-month follow-ups. The scintigrams were analyzed by BONE NAVITM version 1 and the BSI value was calculated. Additionally, serum cancer antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) were measured. The patients were divided in 2 distinct groups—group A representing all follow-up BSI values ≤ initial BSI values and group B representing all follow-up BSI values ≥ initial BSI values. The interval changes of CA15-3 and CEA were divided in the same fashion. Kaplan-Meier method and log-rank test revealed that the overall survival rate was significantly greater in group A than those of group B after 6 months (p = 0.011) and 12 months (p = 0.016). Univariate analysis revealed that the overall survival rate was significantly greater in group A than those of group B, after a 6 month period (Hazard Ratio [HR] 5.841; 95% confidence interval [CI] 1.248 - 27.34; p = 0.025) and 12 month period (HR: 4.22; 95% CI 1.17615.15; p = 0.027). Multivariate analysis demonstrated that BSI changes after 6 and 12 months trended toward significance regarding parameters affecting survival rate (age and CA15-3) with a HR = 12.760 (95%CI 1.8110 - 89.850) at 6 months with a p = 0.010 and a HR = 5.0640 (95%CI 1.0590 - 24.220) at 12 months with a p = 0.042. BSI changes after 6 and 12 months appear to be a prognostic factor in breast cancer patients with bone metastasis treated with zoledronic acid.

Cite this paper
Okada, Y. , Abe, T. , Nakajima, Y. , Okuda, I. , Lohman, B. , Kanemaki, Y. , Kojima, Y. and Tsugawa, K. (2015) Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid. Open Journal of Radiology, 5, 149-158. doi: 10.4236/ojrad.2015.53022.
[1]   Makita, M., Iwase, T., Tada, T., Takahashi, K., Tada, K., Nishimura, S., Yoshimoto, M., Kasumi, F., Akiyama, F. and Sakamoto, G. (2004) The Site and Timing of the First Recurrence of Breast Cancer. Japanese Journal of Breast Cancer, 19, 343-351.

[2]   Pivot, X., Asmar, L., Hortobagyi, G.N., Theriault, R., Pastorini, F. and Buzdar, A.R. (2003) Retrospective Study of First Indicators of Breast Cancer. Breast Cancer, 10, 335-340.

[3]   Brennan, M.E. and Houssami, N. (2012) Evaluation of the Evidence on Staging Imaging for Detection of Asymptomatic Distant Metastases in Newly Diagnosed Breast Cancer. Breast, 21, 112-123.

[4]   Myers, R.E., Johnstion, M., Pritchard, K., Levine, M. and Oliver, T. (2001) Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline Staging Tests in Primary Breast Cancer: A Practice Guideline. CMAJ, 164, 1439-1444.

[5]   Sadik, M., Suurkula, M., Hoglund, P., Jarund, A. and Edenbrandt, L. (2009) Improved Classifications of Planar Whole Body Bone Scans Using a Computer-Assisted Diagnosis System a Multicenter, Multiple-Reader, Multiple-Case Study. The Journal of Nuclear Medicine, 50, 368-375.

[6]   Erdi, Y.E., Humm, J.L., Lmbriaco, M., Yeung, H. and Larson, S.M. (1997) Quantitative Bone Metastases Analysis Based on Image Segmentation. The Journal of Nuclear Medicine, 38, 1401-1406.

[7]   Mitsui, Y., Shiina, H., Yamamoto, Y., Haramoto, M., Arichi, N., Yasumoto, H., Kitagaki, H. and Igawa, M. (2012) Prediction of Survival Benefit Using an Automated Bone Scan Index in Patients with Castration-Resistant Prostate Cancer. BJU International, 110, E628-E634.

[8]   Imbriaco, M., Larson, S.M., Yeung, H.W., Mawlawi, O.R., Erdi, Y., Venkatraman, E.S. and Scher, H.I. (1998) A New Parameter for Measuring Metastatic Bone Involvement by Prostate Cancer the Bone Scan Index. Clinical Cancer Research, 4, 1765-1772.

[9]   Dennis, E.R., Jia, X., Mezheritskiy, I.S., Stephenson, R.D., Schoder, H., Fox, J.J., Heller, G., Scher, H.I., Larson, S.M. and Morris, M.J. (2012) Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 30, 519-524.

[10]   Horikoshi, H., Kikuchi, A. and Onoguch, M. (2012) Computer-Aided Diagnosis System for Bone Scintigrams from Japanese Patients: Importance of Training Database. Annals of Nuclear Medicine, 26, 622-626.

[11]   Suzuki, C., Jacobsson, H., Hatschek, T., Torkzad, M.R., Bodén, K., Eriksson-Alm, Y., Berg, E., Fujii, H., Kubo, A. and Blomqvist, L. (2008) Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations. RadioGraphics, 28, 329-344.

[12]   Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinsten, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweji, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.

[13]   Soloway, M.S., Hardeman, S.W. and Hickey, D. (1998) Stratification of Patients with Metastatic Prostate Cancer Based on Extent of Disease on Initial Bone Scan. Cancer, 61, 195-202.

[14]   Colomer, R., Rubal, A., Genollá, J., Rubio, D., Del Campo, J.M., Bodi, R. and Salvador, L. (1993) Circulating CA 15-3 Levels in the Postsurgical Follow-Up and in Monitoring Clinical Course of Metastatic Cancer in Patients with Breast Carcinoma. European Journal of Surgical Oncology, 19, 74-79.

[15]   Safi, F., Kohler, J., Rottinger, E. and Beger, H. (1991) The Value of the Tumor Marker CA 15-3 in Diagnosing and Monitoring Breast Cancer. A Comparative Study with Carcinoembryonic Antigen. Cancer, 68, 574-582.

[16]   Kokko, R., Holli, K. and Hakama, M. (2002) Ca 15-3 in the Follow-Up of Localized Breast Cancer: A Prospective Study. European Journal of Cancer, 38, 1189-1193.

[17]   Harris, L., Fritsche, H., MAennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M.R., Hayes, D.F. and Best Jr., R.C. (2007) American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology, 25, 5287-5312.

[18]   Best, R.C. (2000) 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1865-1878.

[19]   Kurebayashi, J., Yamamoto, Y., Tanaka, K., Kohno, N., Kurosumi, M., Moriya, T., Nishimura, R., Ogawa, Y. and Taguchi, T. (2003) Significance of Serum Carcinoembryonic Antigen and CA 15-3 in Monitoring Advanced Breast Cancer Patients Treated with Systemic Therapy: A Large-Scale Retrospective Study. Breast Cancer, 10, 38-44.

[20]   Iwase, T., Yamamoto, N., Ichihara, H., Togawa, T., Nagashima, T. and Miyazaki, M. (2014) The Relationship between Skeletal-Related Events and Bone Scan Index for the Treatment of Bone Metastasis with Breast Cancer Patients. Medicine, 93, e269.

[21]   Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y. and Takashima, S. (2005) Zoledronic Acid Significantly Reduces Skeletal Complications Compared with Placebo in Japanese Women with Bone Metastases from Breast Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 23, 3314-3321.

[22]   Berenson, J.R. (2005) Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastasis. Oncologist, 10, 52-62.